Circulating tumour DNA—looking beyond the blood

A Tivey, M Church, D Rothwell, C Dive… - Nature reviews clinical …, 2022 - nature.com
Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond

L Keller, Y Belloum, H Wikman, K Pantel - British journal of cancer, 2021 - nature.com
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells

L Keller, K Pantel - Nature Reviews Cancer, 2019 - nature.com
Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …

Life and death of circulating cell-free DNA

A Kustanovich, R Schwartz, T Peretz… - Cancer biology & …, 2019 - Taylor & Francis
Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …

Current and future clinical applications of ctDNA in immuno-oncology

JC Stadler, Y Belloum, B Deitert, M Sementsov… - Cancer Research, 2022 - AACR
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers

G Castellani, M Buccarelli, MB Arasi, S Rossi… - Cancers, 2023 - mdpi.com
Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …

[HTML][HTML] Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

L Tan, S Sandhu, RJ Lee, J Li, J Callahan, S Ftouni… - Annals of …, 2019 - Elsevier
Background The advent of effective adjuvant therapies for patients with resected melanoma
has highlighted the need to stratify patients based on risk of relapse given the cost and …

Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma

Y Cao, CT Haring, C Brummel, C Bhambhani… - Clinical Cancer …, 2022 - AACR
Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC),(i) to
investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and …

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

T Seremet, Y Jansen, S Planken, H Njimi… - Journal of translational …, 2019 - Springer
Background Treatment with anti-PD1 monoclonal antibodies improves the survival of
metastatic melanoma patients but only a subgroup of patients benefits from durable disease …

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

MM Syeda, JM Wiggins, BC Corless, GV Long… - The lancet …, 2021 - thelancet.com
Background Melanoma lacks validated blood-based biomarkers for monitoring and
predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising …